Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

Mayu Ohuchi,Shigehiro Yagishita,Hitomi Jo,Kazumasa Akagi,Ryoko Inaba Higashiyama,Ken Masuda,Yuki Shinno,Yusuke Okuma,Tatsuya Yoshida,Yasushi Goto,Hidehito Horinouchi,Yoshinori Makino,Noboru Yamamoto,Yuichiro Ohe,Akinobu Hamada

Lung Cancer（2022）

引用 3|浏览18

暂无评分

摘要

•PPK model of 200 mg Q3W pembrolizumab in Japanese patients with NSCLC is developed.•Early change in CL of pembrolizumab correlated with treatment effect and survival.•The time-varying CL reflects the general condition improvement with pembrolizumab.•The CL of pembrolizumab 200 mg Q3W in Japanese is lower than that of Westerners.

查看译文

关键词

Lung cancer,Population pharmacokinetics,Pembrolizumab,Monoclonal antibody,Immune checkpoint inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要